Antiplatelet activity of L-sulforaphane by regulation of platelet activation factors, glycoprotein IIb/IIIa and thromboxane A2

Blood Coagulation and Fibrinolysis

Volumn 24, Issue 5, 2013, Pages 498-504

  Oh, Chung Hun ^a,b   Shin, Jang In ^a,b   Mo, Sang Joon ^b   Yun, Sung Jo ^b   Kim, Sung Hoon ^c   Rhee, Yun Hee ^a,b  

^a Dankook University   (South Korea)

^b Dankook University   (South Korea)

^c Kyung Hee University   (South Korea)

Author keywords

Glycoprotein IIb IIIa; L sulforaphane; platelet aggregation; thromboxane A2

Indexed keywords

ADENOSINE DIPHOSPHATE; ADRENALIN; ANTICOAGULANT AGENT; COLLAGEN; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; L SULFORAPHANE; PROSTAGLANDIN SYNTHASE; SULFORAPHANE; THROMBIN; THROMBOXANE A2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG EMBOLISM; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTHROMBIN TIME; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADENOSINE DIPHOSPHATE; ANIMALS; BLOOD COAGULATION; BLOOD PLATELETS; COLLAGEN; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MICE; MICE, INBRED ICR; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PULMONARY EMBOLISM; THIOCYANATES; THROMBIN; THROMBOXANE A2;

EID: 84879926131     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32835e4275     Document Type: Article

References (29)

1. Cowan DH. Platelet adherence to collagen: role of prostagladin- thromboxane synthesis. Br J Haematol 1981; 49:425-434.
2. Arrebola MM, De la Cruz JP, Villalobos MA, Pinacho A, Guerrero A, Sanchez de la Cuesta F. In vitro effects of clopidogrel on the platelet-subendothelium interaction, plateletthromboxane and endothelial prostacyclin production, and nitric oxide synthesis. J Cardiovasc Pharmacol 2004; 43:74-82.
3. Yao SK, Ober JC, Mcnatt J. ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured caninecoronart arteries. Circ Res 1992; 70:39-48.
4. Phillips DR, Law D, Scarborough RM. Glycoprotein IIb-IIIa in platelet aggregation: an emerging target for the prevention of acute coronary thrombotic occlusions. Arch Pathol Lab Med 1998; 122:811-812.
5. Aszodi A, Pfeifer A, Ahmad M, Glauner M, Zhou XH, Ny L. The Vasolidator-stimulated phosphoprotein (VASP) is involved in c GMP-and c AMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. EMBO J 1999; 8:37-48.
6. Pignatelli P, Pulcinelli FM, Lenti L, Gazzaniga PP, Violi F. Hydrogen peroxide is involved in collagen-induced platelet activation. blood 1998; 91:484-490.
7. Smith WL, De Witt DL, Garavito RM. Cyclooxygenases:structural, cellular, and molecular biology. Annu Rev Biochem 2000; 69:145-182.
8. Berger PB. Clopidogrel after coronary stenting. Curr Intervent Cardiol Rep 1999; 1:263-269.
9. Talalay P, Fahey JW, Holtzclaw WD, Prestera T, Zhang Y. Chemoprotection against cancer by phase 2 enzyme induction. Toxicol Lett 1995; 82-83:173-179.
10. Hahm ER, Singh SV. Sulforaphane inhibits constitutive and interleukin-6-induced activation of signal transducer and activator of transcription 3 in prostate cancer cells. Cancer Prev Res (Phila) 2010; 3:484-494.
11. Sharma R, Sharma A, Chaudhary P, Pearce V, Vatsyayan R, Singh SV, et al. Role of lipid peroxidation in cellular responses to D, L-sulforaphane, a promising cancer chemopreventive agent. Biochemistry 2010; 49:3191-3202.
12. Kim SH, Singh SV. D, L-Sulforaphane causes transcriptional repression of androgen receptor in human prostatecancercells. Mol Cancer Ther 2009; 8:1946-1954.
13. Xiao D, Powolny AA, Antosiewicz J, Hahm ER, Bommareddy A, Zeng Y, et al. Cellular responses to cancer chemopreventive agent D, L-sulforaphane in human prostate cancer cells are initiated by mitochondrial reactive oxygen species. Pharm Res 2009; 26:1729-1738.
14. Singh SV, Warin R, Xiao D, Powolny AA, Stan SD, Arlotti JA, et al. Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells. Cancer Res 2009; 69:2117-2125.
15. Mikolajewska P, Juzeniene A, Moan J. Effect of (R)L-sulforaphane on 5-aminolevulinic acid-mediated photodynamic therapy. Transl Res 2008; 152:128-133.
16. Yeung EY, Sueyoshi T, Negishi M, Chang TK. Identification of Ginkgo biloba as a novel activator of pregnane X receptor. Drug Metab Dispos 2008; 36:2270-2276.
17. Mays JR, Weller Roska RL, Sarfaraz S, Mukhtar H, Rajski SR. Identification, synthesis, and enzymology of nonnatural glucosinolate chemopreventive candidates. Chembiochem 2008; 9:729-747.
18. Herman-Antosiewicz A, Xiao H, Lew KL, Singh SV. Induction of p21 protein protects against sulforaphane-induced mitotic arrest in LNCa P human prostate cancer cell line. Mol Cancer Ther 2007; 6:1673-1681.
19. Choi S, Lew KL, Xiao H, Herman-Antosiewicz A, Xiao D, Brown CK, et al. D, L-Sulforaphane-induced cell death in human prostate cancer cells is regulated by inhibitor of apoptosis family proteins and Apaf-1. Carcinogenesis 2007; 28:151-162.
20. Nishizawa E, Wynalda DJ. Inhibitory effect of ibuprofen (Motrin) on platelet function. Thromb Res 1981; 21:347-356.
21. Yuk DY, Ryu CK, Hong JT, Chung KH, Kang WS, Kim Y. Antithrombotic and antiplatelet activities of 2-chloro-3-[4-(ethylcarboxy0-phenyl)-amino-1, 4-naphtoquinone (NQ12), a newly synthesized 1, 4-naphtoquinone derivative. Biochem Pharmacol 2000; 60:1001-1008.
22. Cha YJ, Chang EA, Kim CH. Effects of endothelial cells and mononuclear leukocytes on platelet aggregation. Haematologia (Budap) 2000; 30:97-106.
23. Hagberg IA, Solvik UO, Opdahl H, Roald HE, Lyberg T. Inhalation of nitric oxide inhibits ADP-induced plateletaggregation and alpha-granule release. Platelets 1999; 10:382-390.
24. Bode-Boger SM, Boger RH, Galland A, Frolich JC. Differential inhibition of human platelet aggregation and thromboxane A2 formation by L-arginine in vivo and in vitro. Naunyn Schmiedebergs Arch Pharmacol 1998; 357:143-150.
25. Chiang TM, Cole F, Woo-Rasberry V, Kang ES. Roleofnitricoxidesynthase in collagen-platelet interaction: involvement of platelet nonintegrin collagen receptor nitrotyrosylation. Thromb Res 2001; 102:343-352.
26. Mogielnicki A, Kramkowski K, Pietrzak L, Buczko W. N-methylnicotinamide inhibitsarterialthrombosis in hypertensive rats.JPhysiol Pharmacol 2007; 58:515-527.
27. Odawara A, Kikkawa K, Katoh M, Toryu H, Shimazaki T, Sasaki Y. Inhibitory effects of TA-993, a new 1, 5-benzothiazepine derivative, on platelet aggregation. Circ Res 1996; 78:643-649.
28. Sirmagul B, Ozdener F, Gulbas Z, Erol K. Calcium channel blockers increase the amount of nitrite production in rabbits without decreasing the responsiveness of platelets to collagen. Clin Exp Med 2007; 7:142-148.
29. Tang Z, Wang Y, Xiao Y, Zhao M, Peng S. Antithrombotic activity of PDR, a newly synthesized L-Arg derivative, on three thrombosis models in rats. Thromb Res 2003; 110:127-133. Technology